<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126954</url>
  </required_header>
  <id_info>
    <org_study_id>2019_CALCI-CINA</org_study_id>
    <nct_id>NCT04126954</nct_id>
  </id_info>
  <brief_title>Study on the Use of Cinacalcet in Phosphocalcic Context.</brief_title>
  <acronym>CALCI-CINA</acronym>
  <official_title>Multicentric Retrospective Study on the Use of Cinacalcet in an Off-label Phosphocalcic Context</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, the indications used for MA (Marketing Authorization) Cinacalcet in France are
      hyperparathyroidism (hyperPTH) in adults, whether primary (for patients in whom
      parathyroidectomy is theoretically indicated but in whom it is contraindicated or not is not
      clinically appropriate) or secondary to a chronic kidney disease, and parathyroid carcinomas.

      In pediatric patients, data on its use are restricted due to its recent marketing
      authorization (2017) and limited to dialysis patients suffering from secondary hyperPTH.

      Nevertheless, some patients with phosphocalcic pathologies without renal insufficiency must
      be treated off-label by cinacalcet in the presence of severe hyperPTH, without any other
      chronic treatment available to date.

      The objective of this study is therefore to evaluate the use in France of cinacalcet in
      phosphocalcic pathologies without renal insufficiency, in order to obtain efficacy and safety
      data in order to improve our knowledge on the management of these orphan diseases.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum PTH concentration</measure>
    <time_frame>3 months after treatment initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum PTH concentration</measure>
    <time_frame>1 month after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PTH concentration</measure>
    <time_frame>6 months after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PTH concentration</measure>
    <time_frame>12 months after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PTH concentration</measure>
    <time_frame>3 years after treatment initiation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hyperparathyroidism, Secondary</condition>
  <condition>Hyperparathyroidism, Primary</condition>
  <arm_group>
    <arm_group_label>Cinacalcet</arm_group_label>
    <description>Patients with primary or secondary hyperPTH resulting from phosphocalcic pathology treated by cinacalcet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum PTH concentrations results</intervention_name>
    <description>To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.</description>
    <arm_group_label>Cinacalcet</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with phosphocalcic diseases suffering from hyperPTH without end-stage renal
        failure.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with phosphocalcic pathology without end-stage renal failure

          -  Patients followed in one of the hospitals of the centers of reference and competence
             of the diseases of the metabolism of calcium and phosphate

          -  For children under 18: patient and parent (s) / parent having been informed of the
             study and having expressed their on-opposition

          -  For adults: patient / legal guardian of the patient under guardianship having been
             informed of the study and expressing his or her non opposition

        Exclusion Criteria:

          -  Patient suffering from parathyroid cancer,

          -  Patient suffering from primary hyperPTH in whom parathyroidectomy would theoretically
             be indicated but contraindicated or clinically inappropriate,

          -  Patient suffering from hyperPTH secondary to end-stage renal failure

          -  No social security support
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justine BACCHETTA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Néphrologie, Rhumatologie et Dermatologie Pédiatriques</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justine BACCHETTA, MD</last_name>
    <phone>4 27 85 61 30</phone>
    <phone_ext>+33</phone_ext>
    <email>justine.bacchetta@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sacha FLAMMIER, PHD</last_name>
    <phone>4 27 85 66 69</phone>
    <phone_ext>+33</phone_ext>
    <email>sacha.flammier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endocrinologie Diabète et Maladies Métaboliques - Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Igor TAUVERON, PR</last_name>
      <phone>4 73 75 15 33</phone>
      <phone_ext>+33</phone_ext>
      <email>itauveron@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie Pédiatrique -Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert NOVO, MD</last_name>
      <phone>03.20.44.46.95</phone>
      <phone_ext>+33</phone_ext>
      <email>robert.novo@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie Pédiatrique - Hôpital de la mère et de l'Enfant</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne LIENHARDT-ROUSSIE, MD</last_name>
      <phone>5.55.05.63.58</phone>
      <phone_ext>+33</phone_ext>
      <email>anne.lienhardt@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pole Femme Mère Enfant - Pédiatrie spécialisée - Centre Hospitalier Universitaire</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cyril AMOUROUX, MD</last_name>
      <phone>4 67 33 81 12</phone>
      <phone_ext>+33</phone_ext>
      <email>cyril-amouroux@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie pédiatrique - Clinique Médicale Pédiatrique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emma ALLAIN-LAUNAY, MD</last_name>
      <phone>240083660</phone>
      <phone_ext>+33</phone_ext>
      <email>emma.allainlaunay@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'endocrinologie et Diabétologie Pédiatrique-Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laeticia MARTINERIE, MD</last_name>
      <phone>1.40.03.53.03</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.martinerie@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Diabétologie et endocrinologie pédiatriques - Centre Hospitalier Universitaire</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-François SOUCHON, MD</last_name>
      <email>pfsouchon@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pôle Néphrologie-Urologie-Diabétologie-Endocrinologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nathalie JEANDIDIER, PR</last_name>
      <phone>3 88 11 66 03</phone>
      <phone_ext>+33</phone_ext>
      <email>nathalie.jeandidier@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Maladies Osseuses, Gynécologie, Génétique</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Pierre SALLES, MD</last_name>
      <phone>534558555</phone>
      <phone_ext>+33</phone_ext>
      <email>salles.jp@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unité Endocrinologie, Nutrition, Diabétologie -Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise CRINIERE, MD</last_name>
      <email>lise.criniere@univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperparathyroidism</keyword>
  <keyword>pathology phosphocalcic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

